Abstract
Fragile X syndrome is one of the most common reasons for human hereditary mental retardation. It is associated with the expansion of CGG repeats in the 5'-untranslated region of the FMR1 gene, which results in the suppression of its expression and the development of the disease. At present, methods based on PCR and Southern blot analysis are used for diagnostics of the fragile X syndrome. The presence of a fragile site FRAXA on the X chromosome is typical for patients with this pathology. We developed a method of visualizing this site in cell cultures obtained from patients using the fluorescent in situ hybridization (FISH) and the combination of two probes. The method allows one to detect five types of signals on the X chromosome, three of which are normal, while two are associated with the emergence of fragile site FRAXA. An analysis of the distribution of all signal types in cell lines from healthy individuals and patients with fragile X syndrome demonstrated that the method allows one to determine differences between lines with a high statistical significance and that it is applicable to detecting cells that are carriers of the syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- FXS:
-
fragile X syndrome
- FdU:
-
fluorodeoxyuridine
- FISH:
-
fluorescent in situ hybridization
References
Martin J.P., Bell J. 1943. A pedigree of mental defect showing sex-linkage. J. Neurol. Psychiatry. 6, 154–157.
Saldarriaga W., Tassone F., González-Teshima L.Y., Forero-Forero J.V., Ayala-Zapata S., Hagerman R. 2014. fragile X syndrome. Colombia Médica. 45, 190–198.
Hunter J., Rivero-Arias O., Angelov A., Kim E., Fotheringham I., Leal J. 2014. Epidemiology of fragile X syndrome: A systematic review and meta-analysis. Am. J. Med. Genet. Part A. 164, 1648–1658.
D’Hulst C., Kooy R.F. 2009. Fragile X syndrome: From molecular genetics to therapy. J. Med. Genet. 46, 577–584.
Monaghan K.G., Lyon E., Spector E. 2013. ACMG standards and guidelines for fragile X testing: A revision to the disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American college of medical genetics and genomics. Genet. Med. 15, 575–586.
Gallagher A., Hallahan D. 2012. Fragile X-associated disorders: A clinical overview. J. Neurol. 259, 401–413.
Lokanga R.A., Entezam A., Kumari D., Yudkin D., Qin M., Smith C.B., Usdin K. 2013. Somatic expansion in mouse and human carriers of fragile X premutation alleles. Hum. Mutat. 34, 157–166.
Biancalana V., Steinbach P., Stenhouse S. 2006. Draft best practice guidelines for molecular analysis in fragile X syndrome. Eur. Mol. Genet. Quality Network. http://www.emqn.org/emqn/digitalAssets/0/233_EMQN_guidelines_FRAX_2006.pdf.
Houdayer C., Lemonnier A., Gerard M., Chauve C., Tredano M., Billette de Villemeur T., Aymard P., Bonnefont J.P., Feldmann D. 1999. Improved fluorescent PCR-based assay for sizing CGG repeats at the FRAXA locus. Clin. Chem. Lab. Med. 37, 397–402.
Saluto A., Brussino A., Tassone F., Arduino C., Cagnoli C., Pappi P., Hagerman P., Migone N., Brusco A. 2005. An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. J. Mol. Diagn. 7, 605–612.
Khaniani M.S., Kalitsis P., Burgess T., Slater H.R. 2008. An improved diagnostic PCR assay for identification of cryptic heterozygosity for CGG triplet repeat alleles in the fragile X gene (FMR1). Mol. Cytogenet. 1, 5.
Filipovic-Sadic S., Sah S., Chen L., Krosting J., Sekinger E., Zhang W., Hagerman P.J., Stenzel T.T., Hadd A., Latham G.J., Tassone F. 2010. A novel FMR1 PCR method for the routine detection of low-abundance expanded alleles and full mutations in fragile X syndrome. Clin. Chem. 56, 399–408.
Seneca S., Lissens W., Endels K., Caljon B., Bonduelle M., Keymolen K., de Rademaeker M., Ullmann U., Haentjens P., Van Berkel K., Van Dooren S. 2012. Reliable and sensitive detection of fragile X (expanded) alleles in clinical prenatal DNA samples with a fast turnaround time. J. Mol. Diagn. 14, 560–568.
Tassone F., Pan R., Amiri K., Taylor A.K., Hagerman P.J. 2008. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J. Mol. Diagn. 10, 43–49.
Tassone F. 2015. Advanced technologies for the molecular diagnosis of fragile X syndrome. Exp. Rev. Mol. Diagn. 15, 1465–1473.
Naumann A., Hochstein N., Weber S., Fanning E., Doerfler W. 2009. A distinct DNA methylation boundary in the 5' upstream sequence of the Fmr1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am. J. Hum. Genet. 85, 606–616.
Zhou Y., Law H.Y., Boehm C.D., Yoon C.S., Cutting G.R., Ng I.S.L., Chong S.S. 2004. Robust fragile X (CGG)n genotype classification using a methylation specific triple PCR assay. J. Med. Genet. 41, e45.
Coffee B., Keith K., Albizua I., Malone T., Mowrey J., Sherman S.L., Warren S.T. 2009. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am. J. Hum. Genet. 85, 503–514.
Strelnikov V.V., Nemtsova M.V., Chesnokova G.G., Kuleshov N.P., Zaletaev D.V. 1999. Diagnosis of the Martin–Bell syndrome based on structural and functional alterations in the 5'-untranslated region of the FMR1 gene. Mol. Biol. (Moscow). 33 (2) 288–294.
Lukusa T., Fryns J.P. 2008. Human chromosome fragility. Biochim. Biophys. Acta. 1779, 3–16.
Yudkin D., Hayward B.E., Aladjem M.I., Kumari D., Usdin K. 2014. Chromosome fragility and the abnormal replication of the FMR1 locus in fragile X syndrome. Human Mol. Genetics. 23, 2940–2952.
Sutherland G.R., Baker E., Fratini A. 1985. Excess thymidine induced folate sensitive fragile sites. Am. J. Med. Genet. 22, 433–443.
Grasso M., Boon E.M.J., Filipovic-Sadic S., Van Bunderen P.A., Gennaro E., Cao R., Latham G.J., Hadd A.G., Coviello D.A. 2014. A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without southern blot analysis. J. Mol. Diagn. 16, 23–31.
Smith K.T., Nicholls R.D., Reines D. 2006. The gene encoding the fragile X RNA-binding protein is controlled by nuclear respiratory factor 2 and the CREB family of transcription factors. Nucleic Acids Res. 34, 1205–1215.
Sutherland G.R. 2003. Rare fragile sites. Cytogenet. Genome Res. 100, 77–84.
Kumari D., Somma V., Nakamura A.J., Bonner W.M., D’Ambrosio E., Usdin K. 2009. The role of DNA damage response pathways in chromosome fragility in fragile X syndrome. Nucleic Acids Res. 37, 4385–4392.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © T.S. Bobokova, N.A. Lemskaya, I.S. Kolesnikova, D.V. Yudkin, 2017, published in Molekulyarnaya Biologiya, 2017, Vol. 51, No. 4, pp. 704–709.
Rights and permissions
About this article
Cite this article
Bobokova, T.S., Lemskaya, N.A., Kolesnikova, I.S. et al. Method for the molecular cytogenetic visualization of fragile site FRAXA. Mol Biol 51, 621–626 (2017). https://doi.org/10.1134/S0026893317040069
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893317040069